ElcuBio
Biomedical
Project
Base on a single compound in natural material for developing new drug
- Excavation effective establish experimental standard and method
- Research on efficiency and mechanism identification target protein and biomark
- Preclinical(toxicity), IND application Clinical, NDA application
- Excavation effective establish experimental standard and method
- Research on efficiency and mechanism identification target protein and biomark
- Preclinical(toxicity), IND application Clinical, NDA application
Project Summary
1) Causes of Pressure Ulcer
Pressure ulcers, also called bed sores or pressure sores, are injuries to the skin and underlying tissue resulting from prologed pressure on the skin. It most often develops on skin that covers bony areas of the body, such as heels, ankles, hips, and the tailbone.
Pressure ulcers frequently occur in groups of people having reduced mobility who were hospitalized for long periods of time and elderly or disabled people who cannot move certain body parts without help.
PU is a secondary disease which occurs from ischemic due to insufficient blood circulation, caused by pressure on the bony parts of the body.
2)Stages of Pressure Ulcers
Pressure ulcers (PU) are staged to indicate the extent of tissue damage. The National Pressure Ulcer Advisory Panel (NPUAP) established a staging system for categorizing pressure ulcer injuries. Prolonged unrelieved pressure leads to ischaemia when tissue compression exceeds capillary pressure. At stage 1, PU presents with intact and erythematous skin that does not blanch, but PU appear as a fluid-filled blister at stage 2. At stage 3, necrosis results from tissue hypoxia and ischaemia-reperfusion injury with wound exudate. At stage 4, the ulcer is much deeper and extends into bone or muscle with full tissue loss.
3)Needs of New Drug for Pressure Ulcer
Optimization of controllable healing factors, like clearance of infection and mechanical protection, have mainly been used thus far.
Few targeted treatments have been developed to date, including topical application of growth factors such as bFGF, VEGF, PDGF, EGF; unfortunately, with limited clinical efficacy and frequent side effects.
All are rectricted to treating non-healing wounds, which creates significant economic burdens in the health care system.
There is a need for the development of aggressive and safe treatment and a curable drug for non-healing wounds like PU and Foot Ulcers.
Pressure ulcers, also called bed sores or pressure sores, are injuries to the skin and underlying tissue resulting from prologed pressure on the skin. It most often develops on skin that covers bony areas of the body, such as heels, ankles, hips, and the tailbone.
Pressure ulcers frequently occur in groups of people having reduced mobility who were hospitalized for long periods of time and elderly or disabled people who cannot move certain body parts without help.
PU is a secondary disease which occurs from ischemic due to insufficient blood circulation, caused by pressure on the bony parts of the body.
2)Stages of Pressure Ulcers
Pressure ulcers (PU) are staged to indicate the extent of tissue damage. The National Pressure Ulcer Advisory Panel (NPUAP) established a staging system for categorizing pressure ulcer injuries. Prolonged unrelieved pressure leads to ischaemia when tissue compression exceeds capillary pressure. At stage 1, PU presents with intact and erythematous skin that does not blanch, but PU appear as a fluid-filled blister at stage 2. At stage 3, necrosis results from tissue hypoxia and ischaemia-reperfusion injury with wound exudate. At stage 4, the ulcer is much deeper and extends into bone or muscle with full tissue loss.
3)Needs of New Drug for Pressure Ulcer
Optimization of controllable healing factors, like clearance of infection and mechanical protection, have mainly been used thus far.
Few targeted treatments have been developed to date, including topical application of growth factors such as bFGF, VEGF, PDGF, EGF; unfortunately, with limited clinical efficacy and frequent side effects.
All are rectricted to treating non-healing wounds, which creates significant economic burdens in the health care system.
There is a need for the development of aggressive and safe treatment and a curable drug for non-healing wounds like PU and Foot Ulcers.
Business Model
- Pressure Ulcer: Laboratory and animal experiments for identifying lead candidates and evaulating the
mechanism of the healing effect of PU Pre-Clinical Trials in 2018
- Plans to initiate Clinical Phase 1 study in 2019
- Evaluation of candidates for Foot Ulcer drug, in vitro experiments (in progress)
- Evaluation of candidates for Muscular loss, in vitro experiments (in progress)
- Non-healing or Chronic wound or age-related chronic inflammation
mechanism of the healing effect of PU Pre-Clinical Trials in 2018
- Plans to initiate Clinical Phase 1 study in 2019
- Evaluation of candidates for Foot Ulcer drug, in vitro experiments (in progress)
- Evaluation of candidates for Muscular loss, in vitro experiments (in progress)
- Non-healing or Chronic wound or age-related chronic inflammation
Main Achievements
Patent
- 3 Application for a patent on an application
- 1 Application for material patent
Investment
- VC investment attraction
- 3 Application for a patent on an application
- 1 Application for material patent
Investment
- VC investment attraction
Date of Establishment2016-2-18
AcceleratorBluepoint Partners
StageBiomedical
Date of TIPS Selection2017-6-1